Clinical Trials Logo

Pediculosis clinical trials

View clinical trials related to Pediculosis.

Filter by:

NCT ID: NCT05643820 Completed - Pediculosis Clinical Trials

Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis

Start date: March 1, 2022
Phase: Phase 1
Study type: Interventional

In children, pediculosis is a common ectoparasitic infestation. Infestation of head lice (Pediculus humanus capitis) causes a variety of physical symptoms, including pruritus, excoriation, cervical lymphadenopathy, and conjunctivitis1. It also has a number of negative social consequences, including parental anxiety and stigmatization of infested children2. It is a significant public health issue that primarily affects school-aged children aged 8 to 113. In developing nations, prevalence rates of up to 40% have been reported4. The four urban areas of KPK (NWFP) reported prevalence of 36.7%5. People with a low socioeconomic background and poor hygiene are more likely to be affected6. Pediculosis capitis has been treated using a variety of treatment modalities. They include both physician prescription and over-the-counter medications. Permethrin or ivermectin had been used topically or orally. Permethrin is a neurotoxin that is synthesized. It is a pyrethroid neurotoxic that targets voltage-sensitive Sodium ion receptors in the neurological system of the insect, triggering nerve depolarization, hyperexcitation, muscular paralysis, and, eventually, parasite death7. Ivermectin is antiparasitic medication, it is possible to treat diseases like lymphatic filariasis, and ectoparasite infestations, primarily scabies, with ivermectin because it binds to glutamate gated chloride ion receptors of invertebrates and disrupts neurotransmission8. The rationale of this study is to study while comparing effectiveness of oral ivermectin and topical permethrin in management of pediculosis. The topical medication usage is problematic and had reported drug resistance9. There has been less regional or national research on the effectiveness of oral Ivermectin, so doctors less frequently use it in our department. Instead, the patients are treated for pediculosis capitis with topical Permethrin.

NCT ID: NCT02499549 Terminated - Pediculosis Clinical Trials

Two Treatment Regimens of Cocamide DEA Lotion for Head Lice

Start date: October 1999
Phase: Phase 2/Phase 3
Study type: Interventional

To assess the efficacy and safety of 10% Cocamide DEA using two treatment regimens in the eradication of head lice. To assess the ability of each treatment regimen to kill all viable ova and to assess patient acceptability of the product in use

NCT ID: NCT01966965 Not yet recruiting - PEDICULOSIS Clinical Trials

Efficacy and Safety Study for PIOLIN® Shampoo

ESPX
Start date: July 2014
Phase: Phase 3
Study type: Interventional

This study aims to demonstrate the therapeutic efficacy and safety of Shampoo PIOLIN ® in the treatment of human pediculosis. Will be treated 212 patients aged 2-60 years with the infestation, along with the people in your family life. All will be submitted to the dosing regimen recommended in the package insert. 100% of the sample shall be subjected to clinical evaluation through comb, pre and post treatment and monitored after thirty days for evaluation of safety and possible adverse effects that may arise related to any of the components of the formula. The efficacy study is active comparator, non-inferiority.

NCT ID: NCT01660321 Completed - Pediculosis Clinical Trials

Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation

Start date: September 2011
Phase: Phase 4
Study type: Interventional

A pharmacokinetic and tolerance study of Natroba (spinosad) Topical Suspension, 0.9% in pediatric subjects 6 months to 4 years of age with an active head lice infestation.

NCT ID: NCT01518699 Completed - Pediculosis Clinical Trials

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers.

NCT ID: NCT01336647 Completed - Pediculosis Clinical Trials

An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation

Start date: April 2011
Phase: Phase 2
Study type: Interventional

Phase 2 study to assess the safety and effectiveness of a product to treat children and adults with head lice

NCT ID: NCT00963508 Completed - Pediculosis Clinical Trials

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Start date: August 2009
Phase: Phase 3
Study type: Interventional

In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

NCT ID: NCT00927472 Completed - Pediculosis Clinical Trials

Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice

Start date: August 2009
Phase: Phase 3
Study type: Interventional

In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

NCT ID: NCT00927407 Completed - Pediculosis Clinical Trials

Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice

Start date: July 2009
Phase: Phase 1
Study type: Interventional

In this study, 24 adult patients with head lice will be treated with a topical malathion head lice treatment; 12 patients will be treated with a novel product, Malathion Gel, 0.5%, and other 12 patients will be treated with Ovide Lotion 0.5% marketed by Taro Pharmaceuticals USA, Inc. The primary objective of this study is to compare the blood level exposure of Malathion 0.5% Gel to that of the OVIDE Lotion 0.5%.

NCT ID: NCT00752973 Completed - Pediculosis Clinical Trials

Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

Start date: September 2008
Phase: Phase 2/Phase 3
Study type: Interventional

In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.